Lundbeck

 Lundbeck needs to buy to avoid deepening crisis

 Breaking News on Drug Discovery



All our newsletters  (Related)  Free Newsletter     OK  (Related)  OK

 Search

   OK OK

 since

  All   1 Year   6 Months   3 Months   1 Month









 News Headlines

Emerging targets  (Related) 

Tools and techniques  (Related) 

Research management  (Related) 



 All news articles



July 2007  (Related) 

June 2007  (Related) 

Previous months  (Related) 



 Products & Markets



Product & Supplier News  (Related) 

Market Reports  (Related) 

Events  (Related) 



 Business Tools



Free Newsletters  (Related) 

All Newsletters  (Related) 

All Sites  (Related) 

Corporate News Service  (Related) 

News Syndication  (Related) 

 Free Newsletter

  OK  (Related)  OK



All newsletters  (Related) 

 News Headlines     Research managementHomepage  (Related)  >Research management  (Related)  > Lundbeck needs to...  (Related) 

Email this page  (Related)  |Print in friendly format  (Related)  |News by email  (Related)  |Your comments  (Related)      Lundbeck needs to buy to avoid deepening crisis



 By Mike Nagle



  

   Get the latest Market Reports on  Lundbeck  (Related) 

Cipralex  (Related) 

Lexapro  (Related) 

crisis  (Related) 

   Related News



BioLineRx unveils 'innovative' antipsychotic drug  (Related) 

Merck insomnia drug put to bed  (Related) 

Merck bids for cholesterol market leadership  (Related) 

Arena announces P1 insomnia drug data  (Related) 

 News Archives



All news for July 2007   (Related)  All news for July 2007

All news for June 2007   (Related)  All news for June 2007

 05/07/2007
  -
 In a refreshingly honest interview with a Danish newspaper, the Lundbeck CEO has admitted his company is in crisis and needs to restock its pipeline to avoid making it any worse.



 The pharma firm has been rocked by a series of drug failures and its revenues will be sapped once its leading drug, Cipralex/Lexapro (escitalopram), begins to lose patent protection in 2012. That drug made over DKK 3.5bn (€2.6bn) for Lundbeck  (Related)   in 2006, which was over a third of its total revenue (DKK 9.2bn)



 According to Reuters, Claus Braestrup told the Danish newspaper Jyllands-Posten: "It's definitely not a catastrophe or a deep crisis  (Related)  . But a crisis, yes."



 He explained that Lundbeck is willing to buy in individual drugs or even acquire whole companies to relieve the pressure on its pipeline.



 He said: "I have told the organisation that if there is a drug that fits and that we can buy for a fair price, we must bloody well have it."



 He then reportedly went on to say that Anders Gotzsche, Lundbeck's new chief financial officer, will try to re-structure the organisation such that, if the possibility of an acquisition arose, it could pursue it.



 At the end of May, Lundbeck announced that  desmoteplase  its candidate drug given in the immediate aftermath of an acute ischemic stroke, was no more effective than placebo. The drug is based on  a clot-dissolving protein found in the saliva of the vampire bat  Desmodus rotundus  and was designed to bind to fibrin.



 In-licensing deals are nothing new to Lundbeck; the company has signed over 20 such agreements over the past few years from other firms such as  Garching Innovation, Paion, Teva Pharmaceuticals, Pharmexa, Merck & Co. and Solvay Pharmaceuticals.



 Those deals covered a range of different therapeutic categories including sleep disorders, stroke, Parkinson's disease, Alzheimer's disease and schizophrenia.




E-mail this page to a colleague  (Related) 

Print in friendly format  (Related) 

Market reports, buy online now!  (Related) 



 Alerts on Product & Market Innovations !  Please indicate below your research interests and receive email alerts on relevant product and market innovations - This service is free of charge. Drug discovery



 Analysis and instrumentation



 Chromatography



 Assays and screening



 Cell culture & Equipment



 Compounds and consumables



 Contract services (outsourcing)



 Genomics / Proteomics



 Informatics & IT



 Lab equipment & consumables



 Liquid handling and sample preparation



 Liquid handling and automation



 Production technologies



 Separation and purification







> Subscribe   (Related)  > Subscribe

 Copyright  - Unless otherwise stated all contents of this web site are © 2000/2007 - Decision News Media SAS - All Rights Reserved.

 
For permission to reproduce any contents of this web site, please email our Syndication department:
 
.

 
Full details for the use of materials on this site can be found in the Terms & Conditions  (Related)  .

 Subscribe to Other Decision News Media E-newsletters - Pharmaceutical & Science  Pharmaceutical Technology - Europe

  Pharmaceutical Technology - North America

  Drug Discovery

  Outsourcing Pharma

  Biopharmaceutical Science and Business

  Laboratory Equipment

  Pharma legislation

  Pharma finance

  Clinical Research

  Drug targeting and delivery

  Innovations in pharma IT

  Cardiovascular

  Central Nervous System

  Alimentary & Metabolism

  Respiratory

  Anti-infectives & Vaccines

  Musculoskeletal diseases

  Oncology

  Dermatologicals

  Diagnostics

  Microscopy

  Spectroscopy

  Chromatography and Separations Sciences

  Biochemistry

  Cell & Molecular Biology

  Decision News Media Newsletter

Confirm registration  (Related)  Confirm registrationE-newsletters for food & beverage  (Related) 



 All Decision News Media sites

Food & Beverage Development - Europe  (Related)   - Supplements & Nutrition - Europe  (Related)   - Food Processing & Packaging - Europe  (Related)   - Food Marketing and Retailing  (Related)   - Supplements & Nutrition - North America  (Related)   - Beverage Technology & Markets  (Related)   - Dairy Processing & Markets  (Related)   - Food Safety & Quality Control  (Related)   - Industrial Baking & Snacks  (Related)   - Confectionery & Biscuit Processing  (Related)   - Prepared Food and Meat Processing  (Related)   - Food in Central & Eastern Europe  (Related)   - Food and Beverage in Asia Pacific  (Related)   - Food & Beverage Development - North America  (Related)   - Packaging Technologies & Markets  (Related)   - Food Processing & Packaging - North America  (Related)   - Pharmaceutical Technology - Europe  (Related)   - Drug Discovery  (Related)   - Laboratory Equipment  (Related)   - Biopharmaceutical Science and Business  (Related)   - Outsourcing Pharma  (Related)   - Pharmaceutical Technology - North America  (Related)   - Cosmetics Formulation & Packaging - North America  (Related)   - Cosmetics Formulation & Packaging - Europe  (Related) 

Partners  (Related)   -
About us  (Related)   -
Recommend this Site  (Related)   -
Advertise  (Related)   -
Contact the Editor  (Related)   -
Terms & conditions  (Related)   -
Privacy policy  (Related)   

 © 2003/2007 – Decision News Media SAS – All Rights Reserved.



 Traffic audited by: